期刊文献+
共找到369篇文章
< 1 2 19 >
每页显示 20 50 100
The combined detection of carcinoembryonic antigen,carcinogenic antigen 125,and carcinogenic antigen 19-9 in colorectal cancer patients
1
作者 Ling-Zhen Gong Qian-Wen Wang Jie-Wen Zhu 《World Journal of Gastrointestinal Surgery》 SCIE 2024年第7期2073-2079,共7页
BACKGROUND Hepatic metastases are common and difficult to treat after colorectal cancer(CRC)surgery.The predictive value of carcinoembryonic antigen(CEA),cancer antigen(CA)125 and CA19-9 combined tests for liver metas... BACKGROUND Hepatic metastases are common and difficult to treat after colorectal cancer(CRC)surgery.The predictive value of carcinoembryonic antigen(CEA),cancer antigen(CA)125 and CA19-9 combined tests for liver metastasis is unclear.AIM To evaluate predictive value of combined tests for CEA,CA125,and CA19-9 levels in patients with liver metastases of CRC.METHODS The retrospective study included patients with CRC alone(50 cases)and patients with CRC combined with liver metastases(50 cases)who were hospitalized between January 2021 and January 2023.Serum CEA,CA125 and CA19-9 levels were compared between the two groups,and binary logistic regression was used to analyze the predictive value of the combination of these tumor markers in liver metastasis.In addition,we performed receiver operating characteristic(ROC)curve analysis to assess its diagnostic accuracy.RESULTS The results showed that the serum CEA,CA125 and CA19-9 levels in the CRC with liver metastasis group were significantly higher than those in the CRC alone group.Specifically,the average serum CEA level in the CRC with liver metastasis group was 162.03±810.01 ng/mL,while that in the CRC alone group was 5.71±9.76 ng/mL;the average serum CA125 levels were 43.47±83.52 U/mL respectively.and 13.5±19.68 U/mL;the average serum CA19-9 levels were 184.46±473.13 U/mL and 26.55±43.96 U/mL respectively.In addition,binary logistic regression analysis showed that CA125 was significant in predicting CRC liver metastasis(P<0.05).ROC curve analysis results showed that the areas under the ROC curves of CEA,CA125 and CA19-9 were 0.607,0.692 and 0.586.CONCLUSION These results suggest that combined detection of these tumor markers may help early detection and intervention of CRC liver metastasis,thereby improving patient prognosis. 展开更多
关键词 Colorectal cancer Liver metastasis Serum markers Carcinoembryonic antigen cancer antigen 125 cancer antigen 19-9 Receiver operating characteristic analysis
下载PDF
Combining prognostic value of serum carbohydrate antigen 19-9 and tumor size reduction ratio in pancreatic ductal adenocarcinoma
2
作者 Dong-Qin Xia Yong Zhou +6 位作者 Shuang Yang Fang-Fei Li Li-Ya Tian Yan-Hua Li Hai-Yan Xu Cai-Zhi Xiao Wei Wang 《World Journal of Gastrointestinal Oncology》 SCIE 2024年第3期798-809,共12页
BACKGROUND Pancreatic ductal adenocarcinoma(PDAC)is a common cancer with increasing morbidity and mortality due to changes of social environment.AIM To evaluate the significance of serum carbohydrate antigen 19-9(CA19... BACKGROUND Pancreatic ductal adenocarcinoma(PDAC)is a common cancer with increasing morbidity and mortality due to changes of social environment.AIM To evaluate the significance of serum carbohydrate antigen 19-9(CA19-9)and tumor size changes pre-and post-neoadjuvant therapy(NAT).METHODS This retrospective study was conducted at the Chongqing Key Laboratory of Translational Research for Cancer Metastasis and Individualized Treatment,Chongqing University Cancer Hospital.This study specifically assessed CA19-9 levels and tumor size before and after NAT.RESULTS A total of 156 patients who completed NAT and subsequently underwent tumor resection were included in this study.The average age was 65.4±10.6 years and 72(46.2%)patients were female.Before survival analysis,we defined the post-NAT serum CA19-9 level/pre-NAT serum CA19-9 level as the CA19-9 ratio(CR).The patients were divided into three groups:CR<0.5,CR>0.5 and<1 and CR>1.With regard to tumor size measured by both computed tomography and magnetic resonance imaging,we defined the post-NAT tumor size/pre-NAT tumor size as the tumor size ratio(TR).The patients were then divided into three groups:TR<0.5,TR>0.5 and<1 and TR>1.Based on these groups divided according to CR and TR,we performed both overall survival(OS)and disease-free survival(DFS)analyses.Log-rank tests showed that both OS and DFS were significantly different among the groups according to CR and TR(P<0.05).CR and TR after NAT were associated with increased odds of achieving a complete or near-complete pathologic response.Moreover,CR(hazard ratio:1.721,95%CI:1.373-3.762;P=0.006),and TR(hazard ratio:1.435,95%CI:1.275-4.363;P=0.014)were identified as independent factors associated with OS.CONCLUSION This study demonstrated that post-NAT serum CA19-9 level/pre-NAT serum CA19-9 level and post-NAT tumor size/pre-NAT tumor size were independent factors associated with OS in patients with PDAC who received NAT and subsequent surgical resection. 展开更多
关键词 Pancreatic ductal adenocarcinoma Carbohydrate antigen 19-9 Tumor size Pathologic response Biomarkers
下载PDF
临床特征联合血清CA19-9、HE4对子宫内膜异位症相关卵巢癌症的诊断价值
3
作者 陈丽 赵威 +2 位作者 李珊珊 梁爽 丁瑞敏 《海南医学》 CAS 2024年第1期76-79,共4页
目的 探讨临床特征联合血清糖类抗原(CA) 19-9、人附睾蛋白4 (HE4)对子宫内膜异位症相关卵巢癌症(EAOC)的诊断价值。方法 选择2020年1月至2022年12月在河南中医药大学第三附属医院接受手术且经术后病理确诊为EAOC的43例患者作为观察组,... 目的 探讨临床特征联合血清糖类抗原(CA) 19-9、人附睾蛋白4 (HE4)对子宫内膜异位症相关卵巢癌症(EAOC)的诊断价值。方法 选择2020年1月至2022年12月在河南中医药大学第三附属医院接受手术且经术后病理确诊为EAOC的43例患者作为观察组,按照1∶2的比例抽取同期在我院手术且经术后证实为卵巢子宫内膜异位症(OEM)的86例患者作为对照组。比较两组患者的临床资料及血清CA125、CA19-9和HE4水平,采用多因素Logistic回归分析影响EAOC的独立风险因素,并采用受试者工作特征曲线(ROC)分析临床特征、CA19-9和HE4诊断EAOC的价值。结果 观察组患者的CA19-9和HE4水平分别为[20.99 (17.06,32.40)] U/mL和[64.47 (55.93,72.01)] U/mL,明显高于对照组的[4.98(2.18,10.86)] U/mL和[43.39(34.61,52.40)] U/mL,差异均有统计学意义(P<0.05);观察组患者的CA125水平为[59.85 (39.51,92.26)] pmol/L,明略高于对照组的[56.58 (39.80,80.68)] pmol/L,但差异无统计学意义(P>0.05)。经多因素Logistic回归分析结果显示,CA19-9、HE4、年龄、肿瘤最长径是影响EAOC的风险因素(P<0.05)。经ROC分析结果显示,年龄、肿瘤最长径、CA19-9、HE4联合检测的曲线下面积(AUC)为0.958,明显高于单独检测(年龄:0.857;肿瘤最长径:0.767;CA19-9:0.767;HE4:0.808)(P<0.05)。结论 CA19-9、HE4、年龄、肿瘤最长径可用于预测EAOC,联合检测可提高诊断效能。 展开更多
关键词 子宫内膜异位症 子宫内膜异位症相关卵巢癌症 糖类抗原19-9 人附睾蛋白4 诊断价值
下载PDF
CEA、CA724、CA19-9、CA125联合检测在胃癌患者中的运用价值
4
作者 张清渊 《中国医药指南》 2024年第14期39-42,共4页
目的观察血清癌胚抗原(CEA)、糖类抗原724(CA724)、糖类抗原19-9(CA19-9)、糖类抗原125(CA125)联合检测对胃癌患者的临床价值。方法选取我院2020年5月至2023年5月收治的176例胃癌患者作为恶性组,按照2∶1配对原则选取同期、同年段88名... 目的观察血清癌胚抗原(CEA)、糖类抗原724(CA724)、糖类抗原19-9(CA19-9)、糖类抗原125(CA125)联合检测对胃癌患者的临床价值。方法选取我院2020年5月至2023年5月收治的176例胃癌患者作为恶性组,按照2∶1配对原则选取同期、同年段88名健康对照作为对照组。比较两组血清CEA、CA724、CA19-9、CA125水平,分析胃癌患者血清各指标与临床病理特征的关系,ROC曲线评估血清各指标联合对胃癌的诊断价值。结果恶性组血清CEA、CA724、CA19-9、CA125水平高于对照组(P<0.05);胃癌患者分化程度、TNM分期、淋巴结转移、远处转移血清CEA、CA724、CA19-9、CA125水平比较,差异有统计学意义(P<0.05);血清CEA、CA724、CA19-9、CA125与分化程度、TNM分期、淋巴结转移、远处转移呈正相关(P<0.05);血清CEA、CA724、CA19-9、CA125联合诊断胃癌的AUC大于各指标单独诊断(P<0.05)。结论胃癌患者血清CEA、CA724、CA19-9、CA125表达较高,与患者分化程度、TNM分期、淋巴结转移、远处转移有关,且联合检测胃癌具有较高参考价值。 展开更多
关键词 胃癌 癌胚抗原 糖类抗原724 糖类抗原19-9 糖类抗原125
下载PDF
血清G-17、PGR、CEA、CA19-9及脂联素联合检测在胃癌筛查中的应用研究 被引量:1
5
作者 曹霞 张佳盈 徐满 《实用癌症杂志》 2024年第1期34-37,共4页
目的探讨血清胃泌素-17(G-17)、胃蛋白酶原比值(PGR)、癌胚抗原(CEA)、糖类抗原19-9(CA19-9)及脂联素联合检测在胃癌筛查中的应用价值。方法选取58例胃癌患者作为观察组,同期收治的胃良性疾病患者58例设为对照组。所有患者均采集空腹静... 目的探讨血清胃泌素-17(G-17)、胃蛋白酶原比值(PGR)、癌胚抗原(CEA)、糖类抗原19-9(CA19-9)及脂联素联合检测在胃癌筛查中的应用价值。方法选取58例胃癌患者作为观察组,同期收治的胃良性疾病患者58例设为对照组。所有患者均采集空腹静脉血检测G-17、PGR、CEA、CA19-9及脂联素水平,比较两组血清学指标差异及不同分期胃癌患者血清学指标变化;并绘制ROC曲线,分析血清G-17、PGR、CEA、CA19-9、脂联素单独检测及联合检测诊断胃癌的临床价值。结果观察组G-17[(16.25±2.18)pmol/L]、CEA[(12.84±2.13)ng/mL]、CA19-9[(42.53±4.28)U/mL]水平高于对照组,PGR[(4.89±0.42)]、脂联素[(5.21±1.05)μg/mL]低于对照组,差异有统计学意义(P<0.05);Ⅰ~Ⅱ期胃癌患者G-17[(14.58±1.69)pmol/L]、CEA[(8.64±1.32)ng/mL]、CA19-9[(36.59±4.02)U/mL]水平低于Ⅲ~Ⅳ期患者,PGR[(6.15±1.02)]、脂联素[(7.02±1.15)μg/mL]高于Ⅲ~Ⅳ期患者,差异有统计学意义(P<0.05);绘制ROC曲线分析显示,G-17、PGR、CEA、CA19-9、脂联素单独检测及联合检测诊断胃癌的曲线下面积(AUC)分别为:0.782、0.775、0.784、0.786、0.722、0.950,联合检测诊断价值最高。结论血清G-17、PGR、CEA、CA19-9及脂联素联合检测在胃癌筛查中应用价值高,可提高诊断效能,便于临床早期筛查工作开展。 展开更多
关键词 胃癌 胃泌素-17 胃蛋白酶原比值 癌胚抗原 糖类抗原19-9 疾病筛查
下载PDF
构建癌胚抗原、糖类抗原19-9生存模型公式预测结直肠癌患者生存时间
6
作者 黄俊强 《临床检验杂志》 CAS 2024年第1期67-72,共6页
目的构建术前癌胚抗原(CEA)、糖类抗原19-9(CA19-9)模型,预测结直肠癌(CRC)患者的生存时间。方法收集江门市中心医院就诊的313例CRC患者,利用Beckman Access化学发光免疫分析仪检测CRC患者术前血清CEA、CA19-9水平,运用χ^(2)检验评估其... 目的构建术前癌胚抗原(CEA)、糖类抗原19-9(CA19-9)模型,预测结直肠癌(CRC)患者的生存时间。方法收集江门市中心医院就诊的313例CRC患者,利用Beckman Access化学发光免疫分析仪检测CRC患者术前血清CEA、CA19-9水平,运用χ^(2)检验评估其与CRC患者临床病理参数的关系,Kaplan-Meier生存分析和Cox多因素分析分别评估CRC患者生存及预后。结果CEA、CA19-9均与CRC患者pT、pN、pM分期,临床Ⅰ、Ⅱ、Ⅲ、Ⅳ分期,进展,复发,脉管浸润,转移部位等因素相关(P<0.05)。CEA升高患者的总生存时间(OS)较CEA正常患者缩短(76.85个月vs 110.83个月,P=0.000)。CA19-9升高患者的OS也有相同趋势(P=0.000)。Cox多因素分析发现CEA、CA19-9是预测CRC患者生存的独立因素(HR分别为2.190和2.874;95%CI分别为1.486~3.225和1.947~4.242;P均<0.05)。联合CEA、CA19-9构建模型公式,赋予CEA正常为0分,CEA升高为1分,CA19-9正常为0分,CA19-9升高为1分,并设CC值=CEA评分+CA19-9评分,结果发现CC值最高患者的OS最短,CC值最低患者的OS最长(P<0.05)。结论构建的CEA、CA19-9模型公式可以有效地预测CRC患者预后。 展开更多
关键词 结直肠癌 癌胚抗原 糖类抗原19-9 生存时间
下载PDF
CEA、CA19-9、CA125、CA72-4水平联合检测在直肠癌诊断中的效能
7
作者 徐萌萌 孙其静 《中国民康医学》 2024年第6期123-125,共3页
目的:观察癌胚抗原(CEA)、糖类抗原19-9(CA19-9)、糖类抗原125(CA125)、糖类抗原72-4(CA72-4)水平联合检测在直肠癌诊断中的效能。方法:回顾性分析2021年2月至2023年5月该院收治的78例直肠癌患者的临床资料,作为直肠癌组;回顾性分析同... 目的:观察癌胚抗原(CEA)、糖类抗原19-9(CA19-9)、糖类抗原125(CA125)、糖类抗原72-4(CA72-4)水平联合检测在直肠癌诊断中的效能。方法:回顾性分析2021年2月至2023年5月该院收治的78例直肠癌患者的临床资料,作为直肠癌组;回顾性分析同期该院收治的100例直肠良性肿瘤患者(直肠腺瘤55例,直肠异型增生45例)的临床资料,作为非直肠癌组。比较两组CEA、CA19-9、CA125、CA72-4水平,比较不同直肠肿瘤(直肠癌、直肠腺瘤、直肠异型增生)患者CEA、CA19-9、CA125、CA72-4水平,分析CEA、CA19-9、CA125、CA72-4水平单项及联合检测在直肠癌诊断中的效能(灵敏度、特异度、准确度)。结果:直肠癌组血清CEA、CA19-9、CA125、CA72-4水平均高于非直肠癌组,差异有统计学意义(P<0.05)。不同直肠肿瘤患者CEA、CA19-9、CA125、CA72-4水平比较,差异均有统计学意义(P<0.05)。CEA、CA19-9、CA125、CA72-4水平联合检测诊断直肠癌的准确度、灵敏度、特异度均高于四者单项检测诊断,差异有统计学意义(P<0.05)。结论:CEA、CA19-9、CA125、CA72-4水平联合检测诊断直肠癌的效能高于四者单项检测诊断效能。 展开更多
关键词 直肠癌 诊断 效能 癌胚抗原 癌抗原19-9 癌抗原125 糖类抗原72-4
下载PDF
子宫内膜癌血清CA125水平与CA19-9检测在临床病理分期中的价值研究
8
作者 曾莉 江立千 包杰 《罕少疾病杂志》 2024年第8期88-89,共2页
目的分析子宫内膜癌患者血清糖类抗原125(CA125)与癌抗原19-9(CA19-9)水平检测在临床病理分期中的价值。方法选取2019年7月~2020年8月我院子宫内膜癌患者86例作为实验组,并以1:1配比选取同期健康体检者86例作为健康对照组。对比两组血清... 目的分析子宫内膜癌患者血清糖类抗原125(CA125)与癌抗原19-9(CA19-9)水平检测在临床病理分期中的价值。方法选取2019年7月~2020年8月我院子宫内膜癌患者86例作为实验组,并以1:1配比选取同期健康体检者86例作为健康对照组。对比两组血清CA125水平与CA19-9比较、不同病理分期血清CA125、CA19-9水平,比较CA125、CA19-9单独与联合检测的检出率,分析相关性。结果实验组血清CA125水平与CA19-9水平较健康对照组高(P<0.05);III~IV期患者血清CA125水平较I~II期高;III~IV期患者血清CA19-9水平较I~II期低(P<0.05);血清CA125水平与CA19-9水平联合检测检出率94.19%较血清CA125水平与CA19-9水平单独检测检出率73.26%、69.77%高(P<0.05);Pearson分析结果显示,血清CA125水平和临床病理分期呈正相关,CA19-9水平和临床病理分期呈负相关(P<0.05)。结论子宫内膜癌患者血清CA125水平与CA19-9较高,血清CA125水平与临床病理分期显著正相关,血清CA19-9水平与临床病理分期显著负相关,且联合检测可提高检出率,利于临床疾病鉴别、病情评估。 展开更多
关键词 子宫内膜癌 临床病理分期 血清糖类抗原125 癌抗原19-9
下载PDF
HPV-DNA联合SCC-Ag、CA19-9、AFP检测诊断宫颈癌的临床价值
9
作者 郝培培 张赛英 +1 位作者 孙斌 孙文超 《中国计划生育学杂志》 2024年第8期1923-1926,1932,共5页
目的:分析人乳头瘤病毒DNA(HPV-DNA)联合鳞状细胞癌抗原(SCC-Ag)、糖类抗原19-9(CA19-9)及甲胎蛋白(AFP)检测在宫颈癌诊断中的临床价值。方法:回顾性收集2018年3月-2022年3月本院诊治的宫颈癌患者、宫颈良性病变患者各80例临床资料,分... 目的:分析人乳头瘤病毒DNA(HPV-DNA)联合鳞状细胞癌抗原(SCC-Ag)、糖类抗原19-9(CA19-9)及甲胎蛋白(AFP)检测在宫颈癌诊断中的临床价值。方法:回顾性收集2018年3月-2022年3月本院诊治的宫颈癌患者、宫颈良性病变患者各80例临床资料,分别纳入宫颈癌组、良性病变组,同期健康体检女性50例纳入对照组,比较3组以及宫颈癌组不同FIGO分期患者血清SCC-Ag、CA19-9、AFP表达水平及HPV-DNA、SCC-Ag、CA19-9、AFP阳性率,以病理诊断为“金标准”,评价HPV-DNA、SCC-Ag、CA19-9、AFP单独及联合检测对宫颈癌的诊断效能。结果:宫颈癌组血清SCC-Ag、CA19-9、AFP表达水平均高于良性病变组与对照组,HPV-DNA、SCC-Ag、CA19-9、AFP阳性率均高于良性病变组与对照组,且宫颈癌组Ⅲ~Ⅳ期患者血清SCC-Ag、CA19-9、AFP表达水平均高于Ⅰ~Ⅱ期患者,HPV-DNA、CA19-9、AFP阳性率均高于Ⅰ~Ⅱ期患者(均P<0.05);HPV-DNA、SCC-Ag、CA19-9、AFP联合检测诊断宫颈癌的敏感度(96.3%)、准确度(91.8%)均高于各项单独检测,AFP诊断特异度最高达100.0%(P<0.05)。结论:HPV-DNA联合SCC-Ag、CA19-9、AFP检测可提高宫颈癌的诊断效能。 展开更多
关键词 宫颈癌 人乳头瘤病毒 鳞状细胞癌抗原 糖类抗原19-9 甲胎蛋白 诊断
下载PDF
CA19-9、NLR在胆囊癌根治手术后患者疾病转归中的临床意义
10
作者 王江 崔世昌 +2 位作者 陈晓倩 朱慧云 赵伯艳 《国际医药卫生导报》 2024年第9期1502-1507,共6页
目的探讨糖类抗原19-9(carbohydrate antigen 19-9,CA19-9)、中性粒细胞/淋巴细胞比值(neutrophil to lymphocyte ratio,NLR)在胆囊癌根治手术后患者疾病转归中的临床意义。方法选取2015年1月至2021年12月于临沂市中心医院行胆囊癌根治... 目的探讨糖类抗原19-9(carbohydrate antigen 19-9,CA19-9)、中性粒细胞/淋巴细胞比值(neutrophil to lymphocyte ratio,NLR)在胆囊癌根治手术后患者疾病转归中的临床意义。方法选取2015年1月至2021年12月于临沂市中心医院行胆囊癌根治术且均完成1年随访的72例胆囊癌患者为胆囊癌组,其中,男39例,女33例,年龄(63.19±3.85)岁。根据1∶1配对原则,另选取同期72例胆囊息肉患者为对照组,其中,男37例,女35例,年龄(62.54±3.52)岁。比较两组入院时血清CA19-9水平、NLR,比较入院时、术后1周不同疾病转归胆囊癌患者血清CA19-9水平、NLR,比较不同病理学参数胆囊癌患者血清CA19-9水平、NLR。Spearman分析入院时血清CA19-9水平、NLR与病理学参数及疾病转归的相关性。采用受试者操作特征曲线(receiver operating characteristic curve,ROC)分析入院时、术后1周血清CA19-9水平、NLR联合检测对胆囊癌患者转归不良的预测价值。结果入院时,胆囊癌组血清CA19-9水平、NLR均高于对照组[(237.14±38.41)U/ml比(31.87±6.43)U/ml、(4.02±1.25)比(1.84±0.43);均P<0.05]。转归不良患者入院时、术后1周血清CA19-9水平、NLR均高于转归良好患者[(261.71±25.33)U/ml比(218.56±24.52)U/ml、(4.73±1.02)比(3.48±0.75),(181.64±28.58)U/ml比(85.43±12.19)U/ml、(3.37±0.48)比(2.24±0.53);均P<0.05]。不同病理参数胆囊癌患者血清CA19-9水平、NLR比较:中高分化患者低于低分化患者[(208.41±22.83)U/ml比(294.60±23.18)U/ml、(3.14±0.47)比(5.78±0.69)],Ⅰ~Ⅱ期患者低于Ⅲ~Ⅳ期患者[(188.43±25.63)U/ml比(276.11±23.08)U/ml、(2.95±0.57)比(4.88±0.64)],无淋巴结转移的患者低于有淋巴结转移的患者[(206.93±24.25)U/ml比(287.49±16.64)U/ml、(3.38±0.49)比(5.09±0.73)],且两指标水平与组织分化程度(r=-0.698、-0.533)呈负相关,与临床分期(r=0.742、0.659)、淋巴结转移(r=0.701、0.634)、疾病转归(r=0.588、0.719)均呈正相关(均P<0.05)。入院时、术后1周血清CA19-9水平、NLR联合预测胆囊癌患者转归不良的曲线下面积(area under the curve,AUC)分别为0.776(95%CI 0.718~0.839)、0.834(95%CI 0.768~0.906),最佳预测灵敏度分别为87.10%、93.55%,最佳预测特异度分别为68.29%、73.17%。结论CA19-9、NLR在胆囊癌根治术后转归不良患者血清中表达上调,两指标与临床病理参数及疾病转归均有一定相关性。两者联合检测对转归情况具有一定预测价值,可作为临床预测根治术后患者转归情况的辅助指标。 展开更多
关键词 胆囊癌 CA19-9 NLR 根治手术 疾病转归 预测价值
下载PDF
血清CEA、CA125、CA19-9、CA72-4水平对胰腺癌患者预后不良的预测价值
11
作者 吴朋 《中国民康医学》 2024年第7期142-144,148,共4页
目的:探讨癌胚抗原(CEA)、糖类抗原(CA)125、CA19-9、CA72-4水平对胰腺癌患者预后不良的预测价值。方法:回顾性分析2021年1月至2023年1月该院收治的73例胰腺癌患者的临床资料,患者均采用FP方案(氟尿嘧啶+顺铂)化疗,根据化疗预后将其分... 目的:探讨癌胚抗原(CEA)、糖类抗原(CA)125、CA19-9、CA72-4水平对胰腺癌患者预后不良的预测价值。方法:回顾性分析2021年1月至2023年1月该院收治的73例胰腺癌患者的临床资料,患者均采用FP方案(氟尿嘧啶+顺铂)化疗,根据化疗预后将其分为预后良好组22例和预后不良组51例。比较两组化疗前血清CEA、CA125、CA19-9、CA72-4水平,采用Logistic回归分析各指标对预后不良的影响,采用受试者工作特征(ROC)曲线分析血清CEA、CA125、CA19-9、CA72-4水平单独及联合检测对胰腺癌患者预后不良的预测价值。结果:化疗前,预后不良组血清CEA、CA125、CA19-9、CA72-4水平均高于预后良好组,差异有统计学意义(P<0.05);Logistic回归分析显示,化疗前血清CEA、CA125、CA19-9、CA72-4水平升高均是胰腺癌患者预后不良的危险因素(P<0.05);ROC曲线分析结果显示,化疗前血清CEA、CA125、CA19-9、CA72-4水平联合检测预测胰腺癌患者预后不良的曲线下面积为0.889,预测价值高于单项指标检测。结论:血清CEA、CA125、CA19-9、CA72-4水平升高是胰腺癌患者预后不良的危险因素,各指标联合检测对预后不良的预测价值高于单项指标检测。 展开更多
关键词 癌胚抗原 糖类抗原125 糖类抗原19-9 糖类抗原72-4 胰腺癌
下载PDF
超声内镜联合血清SCC、CA19-9检测对早期食管癌的诊断价值
12
作者 李娟花 张坤 董亚丽 《实用癌症杂志》 2024年第8期1253-1256,共4页
目的探讨超声内镜(EUS)联合血清鳞状细胞癌抗原(SCC)、糖类抗原19-9(CA19-9)检测在早期食管癌诊断中的应用价值。方法采用EUS探查60例疑似早期食管癌患者,同时应用全自动生化分析仪检测其血清SCC和CA19-9水平。以胃镜下咬检病理检查结... 目的探讨超声内镜(EUS)联合血清鳞状细胞癌抗原(SCC)、糖类抗原19-9(CA19-9)检测在早期食管癌诊断中的应用价值。方法采用EUS探查60例疑似早期食管癌患者,同时应用全自动生化分析仪检测其血清SCC和CA19-9水平。以胃镜下咬检病理检查结果为金标准,分析EUS对早期食管癌的诊断准确性。将研究对象分为食管癌组、非食管癌组,比较两组血清SCC、CA19-9水平差异,并绘制受试者工作特征曲线(ROC)分析血清SCC、CA19-9水平的诊断准确性,及其联合EUS对早期食管癌的诊断效能。结果EUS诊断早期食管癌的准确性、特异性和敏感性依次为90.00%、90.48%、89.74%。与非食管癌组比较,食管癌组血清SCC、CA19-9水平较低(P<0.05)。绘制ROC曲线发现血清SCC、CA19-9诊断早期食管癌的AUC分别为0.705、0.714,截断值分别为0.52μg/L、45.21 U/ml,特异性分别为66.67%、71.79%,敏感性分别为71.43%、76.19%,均为早期食管癌的诊断因子。将患者血清SCC、CA19-9水平与EUS联合用于早期食管癌诊断,其AUC为0.960,特异性为94.87%,高于单一因子(P<0.05)。结论EUS联合血清SCC与CA19-9应用于诊断早期食管癌价值显著,可提高诊断准确性。 展开更多
关键词 超声内镜 鳞状细胞癌抗原 糖类抗原19-9 早期 食管癌 诊断 特异性 敏感性
下载PDF
白细胞介素-2、白细胞介素-4、癌胚抗原、糖类抗原19-9联合检测对结直肠癌的诊断价值及对疗效的预测价值
13
作者 叶施雨 陈秋丹 +1 位作者 赵梦丹 陈佳栋 《癌症进展》 2024年第12期1301-1304,1330,共5页
目的探讨白细胞介素-2(IL-2)、白细胞介素-4(IL-4)、癌胚抗原(CEA)、糖类抗原19-9(CA19-9)联合检测对结直肠癌的诊断价值及对疗效的预测价值。方法选取136例结直肠癌患者和50例健康体检者,比较两组受试者以及不同疗效结直肠癌患者血清I... 目的探讨白细胞介素-2(IL-2)、白细胞介素-4(IL-4)、癌胚抗原(CEA)、糖类抗原19-9(CA19-9)联合检测对结直肠癌的诊断价值及对疗效的预测价值。方法选取136例结直肠癌患者和50例健康体检者,比较两组受试者以及不同疗效结直肠癌患者血清IL-2、IL-4、CA19-9、CEA水平。绘制受试者工作特征(ROC)曲线,计算曲线下面积(AUC),评估IL-2、IL-4、CEA、CA19-9单独及联合检测对结直肠癌的诊断价值及对疗效的预测价值。结果结直肠癌患者血清IL-2水平明显低于健康者,IL-4、CEA、CA19-9水平均明显高于健康者,差异均有统计学意义(P﹤0.01)。ROC曲线显示,IL-2、IL-4、CEA、CA19-9联合检测诊断结直肠癌的AUC为0.910(95%CI:0.853~0.966),高于各指标单独检测,此时的灵敏度为0.971,特异度为0.820。136例结直肠癌患者治疗后,有效95例,无效41例,分别作为有效组和无效组,无效组患者血清IL-2水平明显低于有效组,IL-4、CEA、CA19-9水平均明显高于有效组,差异均有统计学意义(P﹤0.01)。ROC曲线显示,血清IL-2、IL-4、CEA、CA19-9联合检测预测结直肠癌患者疗效的AUC为0.956(95%CI:0.925~0.987),高于各指标单独检测,此时的灵敏度为0.902,特异度为0.916。结论血清IL-2、IL-4、CEA、CA19-9联合检测对结直肠癌的诊断价值及对疗效的预测价值均较高,临床可通过检测上述指标来为结直肠癌的诊疗提供参考。 展开更多
关键词 结直肠癌 白细胞介素-2 白细胞介素-4 癌胚抗原 糖类抗原19-9 诊断
下载PDF
原发性肝癌患者血清α-L-岩藻糖苷酶、糖类抗原724、糖类抗原19-9水平与临床病理特征的相关性分析
14
作者 于兆亚 张孟伟 +1 位作者 陈栋 卢伟伟 《罕少疾病杂志》 2024年第9期74-76,共3页
目的 分析原发性肝癌(PHC)患者血清α-L-岩藻糖苷酶(AFU)、糖类抗原724(CA724)、糖类抗原19-9(CA19-9)水平与临床病理特征的相关性。方法 我院2021年3月至2023年1月收治的71例PHC患者为PHC组,71例同期肝硬化患者为对照组。比较两组入院... 目的 分析原发性肝癌(PHC)患者血清α-L-岩藻糖苷酶(AFU)、糖类抗原724(CA724)、糖类抗原19-9(CA19-9)水平与临床病理特征的相关性。方法 我院2021年3月至2023年1月收治的71例PHC患者为PHC组,71例同期肝硬化患者为对照组。比较两组入院时血清AFU、CA724、CA19-9水平及不同临床病理参数的血清AFU、CA724、CA19-9水平;并分析其相关性;采用ROC进行相关分析。结果 研究组血清AFU、CA724、CA19-9水平高于对照组(t1=15.782;t2=14.195;t3=18.504,P<0.05);不同病理学参数PHC患者血清AFU、CA724、CA19-9水平比较:肿瘤数目(单发)低于肿瘤数目(多发)(t1=5.531;t2=8.155;t3=4.937,P<0.05);肿瘤直径(≤5cm)低于肿瘤直径(>5cm)(t1=7.333;t2=11.808;t3=9.026,P<0.05);Ⅰ~Ⅱ期低于Ⅲ~Ⅳ期(t1=12.733;t2=15.329;t3=15.623,P<0.05);低分化高于中高分化(t1=13.450;t2=26.847;t3=17.349,P<0.05);无淋巴结转移低于有淋巴结转移(t1=14.745;t2=33.192;t3=16.148,P<0.05);入院时血清AFU、CA724、CA19-9水平与分化程度呈负相关,与肿瘤直径、肿瘤数目、淋巴结转移、临床分期呈正相关(P<0.05);入院时血清AFU、CA724、CA19-9水平联合检测PHC的AUC为0.878(95%CI:0.857~0.890,P<0.05)。结论 血清AFU、CA724、CA19-9水平与PHC关系密切,可作为临床诊断的辅助参考指标。 展开更多
关键词 Α-L-岩藻糖苷酶 糖类抗原724 糖类抗原19-9 病理特性 原发性肝癌
下载PDF
血清Bcl-2、IGF-1、CA19-9水平联合检测对食管癌的诊断价值
15
作者 朱银峰 史豫家 《中国民康医学》 2024年第14期131-133,共3页
目的:分析血清B细胞淋巴瘤-2(Bcl-2)、胰岛素样生长因子-1(IGF-1)、糖类抗原19-9(CA19-9)水平联合检测对食管癌的诊断价值。方法:回顾性分析2020年1月至2023年8月该院收治的126例疑似食管癌患者的临床资料。所有患者均接受血清学检测和... 目的:分析血清B细胞淋巴瘤-2(Bcl-2)、胰岛素样生长因子-1(IGF-1)、糖类抗原19-9(CA19-9)水平联合检测对食管癌的诊断价值。方法:回顾性分析2020年1月至2023年8月该院收治的126例疑似食管癌患者的临床资料。所有患者均接受血清学检测和内镜下病理活检,比较良恶性患者及不同病理特征食管癌患者的血清Bcl-2、IGF-1、CA19-9水平。采用受试者工作特征(ROC)曲线分析血清Bcl-2、IGF-1、CA19-9水平单项及联合检测对食管癌的诊断价值。结果:126例疑似食管癌患者中,病理学检出恶性肿瘤(食管癌)70例,其中鳞癌54例,腺癌16例;良性病变56例,其中不典型增生37例,平滑肌瘤19例。恶性患者血清Bcl-2、IGF-1、CA19-9水平均高于良性患者,高分期、低分化、有淋巴结转移的食管癌患者血清Bcl-2、IGF-1、CA19-9水平高于低分期、中高分化、无淋巴结转移的患者,差异均有统计学意义(P<0.05);ROC曲线分析结果显示,血清Bcl-2、IGF-1、CA19-9水平单项及联合检测诊断食管癌的曲线下面积分别为0.802、0.836、0.767、0.918,联合检测的诊断价值高于单一指标检测。结论:血清Bcl-2、IGF-1、CA19-9水平联合检测诊断食管癌的价值高于单一指标检测。 展开更多
关键词 食管癌 B淋巴细胞瘤-2 胰岛素样生长因子-1 糖类抗原19-9 诊断价值
下载PDF
Diagnostic Value of VEGF,CA 19-9,and CEA in Pancreatic Cancer and Risk Factors of Vascular Invasion
16
作者 Anke Chen Yong Chen 《Journal of Clinical and Nursing Research》 2023年第2期19-24,共6页
Background:Pancreatic cancer is a malignant tumor of the gastrointestinal tract.Due to its insidious onset,most patients with newly diagnosed pancreatic cancer have missed the opportunity for radical surgery,which off... Background:Pancreatic cancer is a malignant tumor of the gastrointestinal tract.Due to its insidious onset,most patients with newly diagnosed pancreatic cancer have missed the opportunity for radical surgery,which offers patients the best chance of survival.The 5-year survival rate of patients with pancreatic cancer can be improved with early diagnosis,and serum tumor makers are an inexpensive and convenient diagnostic tool that is widely used in the diagnosis of malignancies.Objective:To determine the diagnostic value of vascular endothelial growth factor(VEGF),carbohydrate antigen 19-9(CA 19-9),and carcinoembryonic antigen(CEA)in patients with pancreatic cancer and the risk factors of vascular invasion.Methods:An experimental group comprising 52 patients with pancreatic cancer admitted to our department from July 2021 to July 2022 and a control group comprising 21 patients with benign pancreatic diseases during the same period were included in our study.Their serum VEGF,CA 19-9,and CEA levels were detected and compared between the two groups,and the correlation between the three markers in the invaded vessel and non-invaded vessel groups was investigated.The diagnostic value of a single tumor marker and in combination for pancreatic cancer was analyzed,and the three tumor marker levels of the experimental group in different pathological characteristics were detected and compared.Results:The experimental group had higher serum VEGF,CA 19-9,and CEA levels than the control group(P<0.05).Through a receiver operating characteristic(ROC)curve analysis,the combined detection had the highest value for the diagnosis of pancreatic cancer,in which the area under the curve(AUC)was 0.9158(95%CI:0.8415-0.9900),while the sensitivity and specificity were 76.19%and 98.08%,respectively.Serum VEGF and CA 19-9 levels were higher in stage Ⅲ-Ⅳ pancreatic cancer patients and those with tumor metastasis compared with stage Ⅰ-Ⅱ patients and those without metastasis(P<0.05),respectively.Binary logistic regression analysis was performed to determine the risk factors of vascular invasion in pancreatic cancer,and the results showed that only serum VEGF was a risk factor(P<0.05),OR(95%CI):1.001-1.006.Conclusion:Patients with pancreatic cancer have significantly higher serum VEGF,CA 19-9,and CEA levels,and the combined detection of tumor markers is of high clinical value in its diagnosis.In addition,serum VEGF is an independent risk factor of vascular invasion in pancreatic cancer,which can predict vascular invasion to a certain extent. 展开更多
关键词 Pancreatic cancer Tumor markers Vascular endothelial growth factor Carcinoembryonic antigen Carbohydrate antigen 19-9
下载PDF
胰腺癌患者血清糖类抗原19-9、糖类抗原242水平及临床意义 被引量:1
17
作者 孙君拓 芦翼飞 +1 位作者 汪海霞 杜伟鹏 《癌症进展》 2023年第20期2277-2279,2293,共4页
目的探讨胰腺癌患者血清糖类抗原19-9(CA19-9)、糖类抗原242(CA242)水平及临床意义。方法选取110例胰腺癌患者、100例胰腺炎患者和100例健康体检者,检测3组受试者血清CA19-9、CA242水平,比较不同临床特征胰腺癌患者血清CA19-9、CA242水... 目的探讨胰腺癌患者血清糖类抗原19-9(CA19-9)、糖类抗原242(CA242)水平及临床意义。方法选取110例胰腺癌患者、100例胰腺炎患者和100例健康体检者,检测3组受试者血清CA19-9、CA242水平,比较不同临床特征胰腺癌患者血清CA19-9、CA242水平。绘制受试者工作特征(ROC)曲线,计算曲线下面积(AUC),评估血清CA19-9、CA242对胰腺癌的诊断价值。结果胰腺癌患者血清CA19-9、CA242水平均明显高于体检者和胰腺炎患者,胰腺炎患者血清CA19-9、CA242水平均明显高于体检者,差异均有统计学意义(P﹤0.01)。Ⅲ+Ⅳ期、淋巴结转移胰腺癌患者血清CA19-9、CA242水平均明显高于Ⅰ+Ⅱ期、无淋巴结转移的患者,差异均有统计学意义(P﹤0.01)。血清CA19-9、CA242诊断胰腺癌的AUC分别为0.685、0.682。结论CA19-9、CA242在胰腺癌患者血清中的水平较高,且其水平与胰腺癌患者临床分期和淋巴结转移有关,但二者单独检测对胰腺癌的诊断价值有限。 展开更多
关键词 胰腺癌 糖类抗原19-9 糖类抗原242 诊断价值
下载PDF
High level of preoperative carbohydrate antigen 19-9 is a poor survival predictor in gastric cancer 被引量:8
18
作者 A Ra Choi Jun Chul Park +4 位作者 Jie-Hyun Kim Sung Kwan Shin Sang Kil Lee Yong Chan Lee Jae Bock Chung 《World Journal of Gastroenterology》 SCIE CAS 2013年第32期5302-5308,共7页
AIM:To assess the clinical significance and the prognostic value of preoperative serum carbohydrate antigen 19-9(CA 19-9)level in gastric cancer.METHODS:Between January 2005 and December2006,1960 patients underwent su... AIM:To assess the clinical significance and the prognostic value of preoperative serum carbohydrate antigen 19-9(CA 19-9)level in gastric cancer.METHODS:Between January 2005 and December2006,1960 patients underwent surgery for histologically confirmed gastric cancer.Of these,163 patients had elevated serum levels of CA 19-9 preoperatively,and1628 patients had normal serum levels of CA 19-9 preoperatively.For this study,325 patients were selected from the group of 1628 patients by age,sex,and cancer stage to serve as controls.Statistically significant differences in survival rates were calculated using the log-rank test.A P value less than 0.05 was considered statistically significant and was determined using SAS software.RESULTS:The baseline characteristics showed some differences between the two groups with regard to histology.Overall survival(OS)in the elevated and nonelevated group was 37.90 and 68.67 mo,respectively(P<0.001).N stage(P=0.001)was a significant predictor of disease-free survival by multivariate analysis.Also,N stage(P<0.001),and the presence of peritoneal metastasis(P<0.001)remained independent factors in predicting OS by multivariate analysis.Additionally,preoperative serum CA 19-9 levels were significantly associated with OS in univariate(P=0.009)and multivariate(P=0.021)analyses.CONCLUSION:Serum CA 19-9 can be considered an independent prognostic factor in predicting OS in patients anticipating surgery for gastric cancer. 展开更多
关键词 Gastric cancer CARBOHYDRATE antigen 19-9 Disease-free SURVIVAL Overall SURVIVAL
下载PDF
Detection of pancreatic cancer with normal carbohydrate antigen 19-9 using protein chip technology 被引量:4
19
作者 Xiao-Li Jin Bin Xu Yu-Lian Wu 《World Journal of Gastroenterology》 SCIE CAS 2014年第40期14958-14964,共7页
AIM: To develop a method to differentiate pancreatic cancer patients from healthy or benign individuals when carbohydrate antigen (CA) 19-9 is normal.
关键词 Carbohydrate antigen 19-9 DIAGNOSIS Pancreatic cancer SCREENING Surface-enhanced laser desorption/ionization time-of-flight mass spectrometry
下载PDF
Combined preoperative platelet-to-lymphocyte ratio and serum carbohydrate antigen 19–9 level as a prognostic factor in patients with resected pancreatic cancer 被引量:3
20
作者 Teruhisa Sakamoto Hiroaki Saito +3 位作者 Masataka Amisaki Naruo Tokuyasu Soichiro Honjo Yoshiyuki Fujiwara 《Hepatobiliary & Pancreatic Diseases International》 SCIE CAS CSCD 2019年第3期278-284,共7页
Background: Carbohydrate antigen 19–9(CA19-9) is the most frequently used tumor marker and serves as a prognostic indicator in patients with pancreatic cancer(PC). The platelet-to-lymphocyte ratio(PLR) is thought to ... Background: Carbohydrate antigen 19–9(CA19-9) is the most frequently used tumor marker and serves as a prognostic indicator in patients with pancreatic cancer(PC). The platelet-to-lymphocyte ratio(PLR) is thought to be an inflammation-related serum marker. An elevated PLR represents increased inflammatory status and is associated with poor prognosis in patients with various cancers including PC. Methods: This study involved 103 patients with a histopathological diagnosis of pancreatic ductal adenocarcinoma who underwent pancreatectomy. The patients were assessed to determine the prognostic significance of the combination of the PLR and CA19-9 level. Results: Based on the receiver operating characteristic analysis results, the patients were divided into PLR H igh(PLR ≥ 129.1) andPLRLow(PLR < 129.1) groups and into CA19-9High(CA19-9 ≥ 74.0 U/mL) and CA19-9Low(CA19-9 < 74.0 U/mL) groups. The cumulative 5-year overall survival(OS) and disease-specific survival(DSS) rates significantly differed by both the PLR(PLR H igh group: 19.5% and 22.9%;PLRLow group: 39.1% and 45.9%) and CA19-9(CA19-9 H igh group: 19.1% and 25.6%;CA19-9Low group: 41.0% and 41.0%). We then divided the patients into Groups A(PLR L ow/CA19-9Low), B(PLR Low/CA19-9High or PLRHigh/CA19-9Low), and C(PLR H igh/CA19-9High). The cumulative 5-year OS rates in Groups A, B, and C were 44.0%, 31.9%, and 11.9%, respectively( P = 0.002). The cumulative 5-year DSS rates in Groups A, B, and C were 47.7%, 36.4%, and 16.8%, respectively( P = 0.002). Multivariate analysis revealed that the combination of the PLR and CA19-9 was an independent prognostic factor in patients with resected PC. Conclusions: The combination of the PLR and CA19-9 is useful for predicting the prognosis of patients with resected PC. 展开更多
关键词 CA19-9 PANCREATIC cancer Platelet-to-lymphocyte RATIO Prognosis
下载PDF
上一页 1 2 19 下一页 到第
使用帮助 返回顶部